We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
- Authors
Ogasawara, Ken; Wood-Horrall, Rebecca N.; Thomas, Mark; Thomas, Michael; Liu, Liangang; Liu, Mary; Xue, Yongjun; Surapaneni, Sekhar; Carayannopoulos, Leonidas N.; Zhou, Simon; Palmisano, Maria; Krishna, Gopal
- Abstract
<bold>Introduction: </bold>Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and multidrug and toxin extrusion (MATE) 1 and MATE2-K in vitro. The objective of this study was to evaluate the influence of fedratinib on the pharmacokinetics (PK) of digoxin (P-gp substrate), rosuvastatin (OATP1B1/1B3 and BCRP substrate), and metformin (OCT2 and MATE1/2-K substrate).<bold>Methods: </bold>In this nonrandomized, fixed-sequence, open-label study, 24 healthy adult participants received single oral doses of digoxin 0.25 mg, rosuvastatin 10 mg, and metformin 1000 mg administered as a drug cocktail (day 1, period 1). After a 6-day washout, participants received oral fedratinib 600 mg 1 h before the cocktail on day 7 (period 2). An oral glucose tolerance test (OGTT) was performed to determine possible influences of fedratinib on the antihyperglycemic effect of metformin.<bold>Results: </bold>Plasma exposure to the three probe drugs was generally comparable in the presence or absence of fedratinib. Reduced metformin renal clearance by 36% and slightly higher plasma glucose levels after OGTT were observed in the presence of fedratinib. Single oral doses of the cocktail ± fedratinib were generally well tolerated.<bold>Conclusions: </bold>These results suggest that fedratinib has minimal impact on the exposure of P-gp, BCRP, OATP1B1/1B3, OCT2, and MATE1/2-K substrates. Since renal clearance of metformin was decreased in the presence of fedratinib, caution should be exercised in using coadministered drugs that are renally excreted via OCT2 and MATEs.<bold>Trial Registration: </bold>Clinicaltrials.gov NCT04231435 on January 18, 2020.
- Subjects
ORGANIC cation transporters; PHARMACOKINETICS; GLUCOSE tolerance tests; BREAST cancer; BLOOD sugar; DIGOXIN
- Publication
Cancer Chemotherapy & Pharmacology, 2021, Vol 88, Issue 6, p941
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-021-04346-7